Acquired Resistance to Immune Checkpoint Blockade Therapies

Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xianda, Wangmo, Dechen, Robertson, Matthew, Subramanian, Subbaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280955/
https://www.ncbi.nlm.nih.gov/pubmed/32380703
http://dx.doi.org/10.3390/cancers12051161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280955/
https://www.ncbi.nlm.nih.gov/pubmed/32380703
http://dx.doi.org/10.3390/cancers12051161

Ejemplares similares